Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions

Sponsored by Simtra BioPharma Solutions

In this video interview, Bo Watkins, senior vice president of sales and business management at Simtra BioPharma Solutions, discusses how the contract development and manufacturing organization (CDMO) is expanding capacity at its Bloomington, Indiana, operations. Watkins describes the investments as a reflection of Simtra’s growth strategy as the company marks its three-year anniversary. The expansions respond to strong demand signals from customers and to what Simtra sees as unmet needs in the US sterile injectable market.

On the main Bloomington campus, Simtra is adding a building focused on increasing syringe capacity as well as vial and lyophilization capacity, with two high-speed syringe lines and one vial line supported by three lyophilizers. Simtra has also purchased an adjacent property with a 300,000-square-foot building that will house its first high-potency filling line in Bloomington, drawing on 65 years of manufacturing expertise from its site in Halle, Germany. Watkins explains that co-located development services, clinical and commercial filling, secondary packaging, and on-site analytical and quality control testing give customers a one-stop solution, while redundant critical systems, duplicate power, and generator backups are designed to keep lines running.

Biopharmaceutical manufacturers evaluating CDMO outsourcing for sterile injectables will gain insight into how Simtra is pairing new capacity with supply chain resilience. Viewers will come away understanding how Simtra’s matched capabilities in the US and Europe give customers the flexibility to fill at both sites and reduce supply risk as programs move from small-scale clinical work to high-speed commercial production.